TIBBİ KENEVİR VE SAĞLIK: FARMAKOLOJİK BİR DERLEME

Yıl 2021, , 631 - 651, 27.09.2021

Özge Balpınar , Selim Aytaç

https://doi.org/10.33483/jfpau.859372

Cited By: 2

Öz

Amaç: Kenevir antik çağlardan bugüne dek tedavi amaçlı kullanılmakta olan bir bitkidir. Her ne kadar kullanımı içerdiği psikoaktif bileşenler dolayısıyla sınırlandırılmış olsa da, kenevirin tıbbi yönüne dair araştırmalar literatürde oldukça yoğundur. Cannabis sativa L., içerdiği fitokannabinoidler ile endokannabinoid sistemde gen düzeyinde pek çok değişikliğe sebep olabilmektedir. Endokannabinoid sistemin pek çok patolojik durumda potansiyel bir terapötik hedef olabileceğine dair kanıtların derlenmesi hedefiyle bu çalışma ortaya koyulmuştur.

Sonuç ve Tartışma: Endokannabinoid sistem içerisinde yer alan reseptörler, endokannabinoidler veya enzimlerin ekspresyon seviyelerinde meydana gelen değişiklikler, Parkinson, Alzheimer, Huntington gibi hastalıkların patolojileriyle ilişkili olabilmektedir. Aynı zamanda endokannabinoid sistemde meydana gelen değişikliklerin kanser hücrelerinin metastazı, yayılımı, proliferasyonunu etkileyebilmektedir. Buna ek olarak kannabinoidlerin, dolayısıyla kenevirin, nöropatik ağrının tedavisinde rol oynadığı gösterilmiştir. Günümüzde kemoterapiye bağlı bulantı ve kusma tedavisinde kullanılan dronabilon ve nabilon kapsülleri gibi bazı kenevir-temelli tedavi preparatları pek çok ülkede onaylanmış, kullanıma sunulmuştur. Δ9tetrahidrocannabinol/ cannabidiol oromukozal sprey gibi preparatlar da pek çok bölgede kanser hastalarında analjezik olarak ya da multiple skleroz hastalarının kas spastisitelerinin giderilmesinde kullanımı onaylanan preparatlardandır. Ancak endokannabinoid sistemin terapötik etkinlik üzerindeki önemi dikkate alındığında, daha pek çok tıbbi durum için kenevirin standardize edilmiş preparatlarına ve bu doğrultuda daha fazla araştırmaya ihtiyaç duyulmaktadır.

Anahtar Kelimeler

Kannabinoid, kanser, kenevir, nörodejeneretif hastalıklar

Destekleyen Kurum

-

Proje Numarası

-

Teşekkür

-

MEDICAL CANNABIS AND HEALTH: A PHARMACOLOGICAL REVIEW

Öz

Objective: Cannabis sativa L. is a plant that has been used for therapeutic purposes since ancient times. However, its use has been limited due to its content. Cannabis causes many changes at the gene level in the endocannabinoid system with the phytocannabinoids it contains. The aim of this study was to provide evidence that the endocannabinoid system could be a potential therapeutic target in many pathological conditions.

Result and Discussion: The change in the expression levels of receptors, endocannabinoids or enzymes in the endocannabinoid system may be associated with the pathologies of diseases such as Parkinson, Alzheimer, and Huntington. Besides, changes in the endocannabinoid system can affect the migration, proliferation of cancer cells. Also, cannabinoids, have been shown to play a role in the treatment of neuropathic pain. Today, some cannabis-based treatment preparations such as dronabilon and nabilon capsules used in the treatment of chemotherapy-induced nausea and vomiting have been approved and available in many countries. Preparations such as Δ9tetrahydrocannabinol/cannabidiol oromucosal spray are also among the preparations approved for use as analgesic in cancer patients or for the relief of muscle spasticity in multiple sclerosis patients. However, standardized preparations of cannabis and further research are needed for many other medical conditions.

Anahtar Kelimeler

Cannabinoid, Cannabis, cancer, neurodegenerative diseases

Proje Numarası

-

Kaynakça

• Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., . . . Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515-521. doi:10.1212/01.wnl.0000253187.66183.9c
• Alles, S. R. A., & Smith, P. A. (2018). Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev, 70(2), 315-347. doi:10.1124/pr.117.014399
• Amin, M. R., & Ali, D. W. (2019). Pharmacology of Medical Cannabis. Adv Exp Med Biol, 1162, 151-165. doi:10.1007/978-3-030-21737-2_8
• Basavarajappa, B. S., Shivakumar, M., Joshi, V., & Subbanna, S. (2017). Endocannabinoid system in neurodegenerative disorders. J Neurochem, 142(5), 624-648. doi:10.1111/jnc.14098
• Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci, 23(35), 11136-11141. doi:10.1523/jneurosci.23-35-11136.2003
• Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., . . . Romero, J. (2007). Cannabinoid CB<sub>1</sub> and CB<sub>2</sub> Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis. The Journal of Neuroscience, 27(9), 2396. doi:10.1523/JNEUROSCI.4814-06.2007
• Bisogno, T., Katayama, K., Melck, D., Ueda, N., De Petrocellis, L., Yamamoto, S., & Di Marzo, V. (1998). Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem, 254(3), 634-642. doi:10.1046/j.1432-1327.1998.2540634.x
• Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33(2), 195-209. doi:10.1002/phar.1187
• Bridgeman, M. B., & Abazia, D. T. (2017). Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P & T : a peer-reviewed journal for formulary management, 42(3), 180-188. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28250701
• Caffarel, M. M., Andradas, C., Mira, E., Pérez-Gómez, E., Cerutti, C., Moreno-Bueno, G., . . . Sánchez, C. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer, 9, 196. doi:10.1186/1476-4598-9-196
• Cannabinoids in Parkinson's Disease. (2017). Cannabis and Cannabinoid Research, 2(1), 21-29. doi:10.1089/can.2017.0002
• Chung, S. C., Hammarsten, P., Josefsson, A., Stattin, P., Granfors, T., Egevad, L., . . . Fowler, C. J. (2009). A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer, 45(1), 174-182. doi:10.1016/j.ejca.2008.10.010
• Cipriano, M., Häggström, J., Hammarsten, P., & Fowler, C. J. (2013). Association between Cannabinoid CB1 Receptor Expression and Akt Signalling in Prostate Cancer. PLoS One, 8(6), e65798. doi:10.1371/journal.pone.0065798
• Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., . . . Ambler, Z. (2010). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research, 32(5), 451-459. doi:10.1179/016164109X12590518685660
• Console-Bram, L., Marcu, J., & Abood, M. E. (2012). Cannabinoid receptors: nomenclature and pharmacological principles. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), 4-15. doi:https://doi.org/10.1016/j.pnpbp.2012.02.009
• Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., . . . Schram, K. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav, 40(3), 701-708. doi:10.1016/0091-3057(91)90386-g
• Crippa, J. A., Zuardi, A. W., Martín-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol, 24(7), 515-523. doi:10.1002/hup.1048
• Cunha, P., Romão, A., Mascarenhas-Melo, F., Teixeira, H., & Reis, F. (2011). Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. Journal of Pharmacy And Bioallied Sciences, 3(3), 350-360. doi:10.4103/0975-7406.84435
• Curtis, A., Mitchell, I., Patel, S., Ives, N., & Rickards, H. (2009). A pilot study using nabilone for symptomatic treatment in Huntington's disease. Movement Disorders, 24(15), 2254-2259. doi:https://doi.org/10.1002/mds.22809
• Darmani, N. A. (2001). Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav, 69(1-2), 239-249. doi:10.1016/s0091-3057(01)00531-7
• Darmani, N. A. (2001). Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology, 24(2), 198-203. doi:10.1016/s0893-133x(00)00197-4
• DeMorrow, S., Francis, H., Gaudio, E., Venter, J., Franchitto, A., Kopriva, S., . . . Alpini, G. (2008). The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. American journal of physiology. Gastrointestinal and liver physiology, 295(6), G1150-G1158. doi:10.1152/ajpgi.90455.2008
• Denovan-Wright, E. M., & Robertson, H. A. (2000). Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience, 98(4), 705-713. doi:10.1016/s0306-4522(00)00157-3
• Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov, 7(5), 438-455. doi:10.1038/nrd2553
• Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F., Faull, R. L., Hannan, A. J., & Glass, M. (2009). Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 163(1), 456-465. doi:10.1016/j.neuroscience.2009.06.014
• El Banoua, F., Caraballo, I., Flores, J. A., Galan-Rodriguez, B., & Fernandez-Espejo, E. (2004). Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. Neurobiology of Disease, 16(2), 377-385. doi:https://doi.org/10.1016/j.nbd.2004.03.002
• Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B., & Konarska, L. (2007). Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res, 1137(1), 161-169. doi:10.1016/j.brainres.2006.12.060
• Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., . . . Atkinson, J. H. (2009). Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology, 34(3), 672-680. doi:10.1038/npp.2008.120
• Ellison, J. M., Gelwan, E., & Ogletree, J. (1990). Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry, 51(10), 439-440.
• ElSohly, M. A., Radwan, M. M., Gul, W., Chandra, S., & Galal, A. (2017). Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod, 103, 1-36. doi:10.1007/978-3-319-45541-9_1
• Esposito, G., Scuderi, C., Savani, C., Steardo Jr, L., De Filippis, D., Cottone, P., . . . Steardo, L. (2007). Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. British journal of pharmacology, 151(8), 1272-1279. doi:https://doi.org/10.1038/sj.bjp.0707337
• Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz, 30(1), 47-61. doi:10.1007/s00482-015-0084-3
• Fitzcharles, M. A., Ste-Marie, P. A., Häuser, W., Clauw, D. J., Jamal, S., Karsh, J., . . . Walsh, Z. (2016). Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken), 68(5), 681-688. doi:10.1002/acr.22727
• Fowler, C. J., Jonsson, K. O., Andersson, A., Juntunen, J., Järvinen, T., Vandevoorde, S., . . . Smart, D. (2003). Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol, 66(5), 757-767. doi:10.1016/s0006-2952(03)00392-7
• Fraguas-Sánchez, A. I., Martín-Sabroso, C., & Torres-Suárez, A. I. (2018). Insights into the effects of the endocannabinoid system in cancer: a review. British journal of pharmacology, 175(13), 2566-2580. doi:https://doi.org/10.1111/bph.14331
• Frampton, G., Coufal, M., Li, H., Ramirez, J., & DeMorrow, S. (2010). Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. Experimental cell research, 316(9), 1465-1478. doi:10.1016/j.yexcr.2010.03.017
• Glass, M., Faull, R. L., & Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience, 56(3), 523-527. doi:10.1016/0306-4522(93)90352-g
• Gofshteyn, J. S., Wilfong, A., Devinsky, O., Bluvstein, J., Charuta, J., Ciliberto, M. A., . . . Marsh, E. D. (2017). Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases. Journal of Child Neurology, 32(1), 35-40. doi:10.1177/0883073816669450
• Gross, D. W., Hamm, J., Ashworth, N. L., & Quigley, D. (2004). Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology, 62(11), 2095-2097. doi:10.1212/01.wnl.0000127623.03766.75
• Hamerle, M., Ghaeni, L., Kowski, A., Weissinger, F., & Holtkamp, M. (2014). Cannabis and other illicit drug use in epilepsy patients. European Journal of Neurology, 21(1), 167-170. doi:https://doi.org/10.1111/ene.12081
• Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. Neurogastroenterology & Motility, 28(12), 1765-1780. doi:https://doi.org/10.1111/nmo.12931
• Häuser, W., Fitzcharles, M. A., Radbruch, L., & Petzke, F. (2017). Cannabinoids in Pain Management and Palliative Medicine. Dtsch Arztebl Int, 114(38), 627-634. doi:10.3238/arztebl.2017.0627
• Henstridge, C. M. (2012). Off-Target Cannabinoid Effects Mediated by GPR55. Pharmacology, 89(3-4), 179-187. doi:10.1159/000336872
• Hohmann, T., Grabiec, U., Ghadban, C., Feese, K., & Dehghani, F. (2017). The influence of biomechanical properties and cannabinoids on tumor invasion. Cell adhesion & migration, 11(1), 54-67. doi:10.1080/19336918.2016.1183867
• Hurley, M. J., Mash, D. C., & Jenner, P. (2003). Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. Journal of Neural Transmission, 110(11), 1279-1288. doi:10.1007/s00702-003-0033-7
• Hurley, M. J., Mash, D. C., & Jenner, P. (2003). Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm (Vienna), 110(11), 1279-1288. doi:10.1007/s00702-003-0033-7
• Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., . . . Sankar, R. (2015). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome. Epilepsy & Behavior, 47, 138-141. doi:https://doi.org/10.1016/j.yebeh.2015.04.009
• Jacobsson, S. O., Wallin, T., & Fowler, C. J. (2001). Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther, 299(3), 951-959.
• Jean-Gilles, L., Feng, S., Tench, C. R., Chapman, V., Kendall, D. A., Barrett, D. A., & Constantinescu, C. S. (2009). Plasma endocannabinoid levels in multiple sclerosis. Journal of the Neurological Sciences, 287(1), 212-215. doi:https://doi.org/10.1016/j.jns.2009.07.021
• Kalant, H. (2001). Medicinal use of cannabis: history and current status. Pain Res Manag, 6(2), 80-91. doi:10.1155/2001/469629
• Katchan, V., David, P., & Shoenfeld, Y. (2016). Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity Reviews, 15(6), 513-528. doi:https://doi.org/10.1016/j.autrev.2016.02.008
• Kelsey, J. E., Harris, O., & Cassin, J. (2009). The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behavioural Brain Research, 203(2), 304-307. doi:https://doi.org/10.1016/j.bbr.2009.04.035
• Kendall, D. A., & Yudowski, G. A. (2017). Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Frontiers in Cellular Neuroscience, 10(294). doi:10.3389/fncel.2016.00294
• Killestein, J., Hoogervorst, E. L., Reif, M., Kalkers, N. F., Van Loenen, A. C., Staats, P. G., . . . Polman, C. H. (2002). Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 58(9), 1404-1407. doi:10.1212/wnl.58.9.1404
• Kleine-Brueggeney, M., Greif, R., Brenneisen, R., Urwyler, N., Stueber, F., & Theiler, L. G. (2015). Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting: A Randomized Controlled Trial. Anesth Analg, 121(5), 1157-1164. doi:10.1213/ane.0000000000000877
• Koppel, J., Vingtdeux, V., Marambaud, P., d’Abramo, C., Jimenez, H., Stauber, M., . . . Davies, P. (2014). CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer’s Disease. Molecular Medicine, 20(1), 29-36. doi:10.2119/molmed.2013.00140.revised
• Laprairie, R. B., Bagher, A. M., & Denovan-Wright, E. M. (2017). Cannabinoid receptor ligand bias: implications in the central nervous system. Current Opinion in Pharmacology, 32, 32-43. doi:https://doi.org/10.1016/j.coph.2016.10.005
• Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., . . . Di Marzo, V. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther, 318(3), 1375-1387. doi:10.1124/jpet.106.105247
• Ligresti, A., Petrocellis, L. D., & Marzo, V. D. (2016). From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiological Reviews, 96(4), 1593-1659. doi:10.1152/physrev.00002.2016
• López-Sendón Moreno, J. L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M. A. A., . . . García de Yébenes Prous, J. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. Journal of Neurology, 263(7), 1390-1400. doi:10.1007/s00415-016-8145-9
• Ma, C., Wu, T.-T., Jiang, P.-C., Li, Z.-Q., Chen, X.-J., Fu, K., . . . Gong, R. (2016). Anti-carcinogenic activity of anandamide on human glioma in vitro and in vivo. Molecular medicine reports, 13(2), 1558-1562. doi:10.3892/mmr.2015.4721
• Maule, W. J. (2015). Medical uses of marijuana (Cannabis sativa): fact or fallacy? British Journal of Biomedical Science, 72(2), 85-91. doi:10.1080/09674845.2015.11666802
• McCaw, E. A., Hu, H., Gomez, G. T., Hebb, A. L., Kelly, M. E., & Denovan-Wright, E. M. (2004). Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem, 271(23-24), 4909-4920. doi:10.1111/j.1432-1033.2004.04460.x
• Mechoulam, R., Peters, M., Murillo-Rodriguez, E., & Hanus, L. O. (2007). Cannabidiol--recent advances. Chem Biodivers, 4(8), 1678-1692. doi:10.1002/cbdv.200790147
• Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., & Baranowski, V. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin, 23(3), 533-543. doi:10.1185/030079907x167525
• Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M., & Di Marzo, V. (2000). Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141(1), 118-126. doi:10.1210/endo.141.1.7239
• Meschler, J. P., Howlett, A. C., & Madras, B. K. (2001). Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl), 156(1), 79-85. doi:10.1007/s002130100728
• Mimeault, M., Pommery, N., Wattez, N., Bailly, C., & Hénichart, J. P. (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate, 56(1), 1-12. doi:10.1002/pros.10190
• Mortati, K., Dworetzky, B., & Devinsky, O. (2007). Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis, 4(2), 103-106.
• Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E., & Campbell, W. B. (2011). Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins & other lipid mediators, 94(1-2), 34-43. doi:10.1016/j.prostaglandins.2010.12.002
• Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain, 133(1-3), 210-220. doi:10.1016/j.pain.2007.08.028
• ONAIVI, E. S., ISHIGURO, H., GONG, J.-P., PATEL, S., PERCHUK, A., MEOZZI, P. A., . . . UHL, G. R. (2006). Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain. Annals of the New York Academy of Sciences, 1074(1), 514-536. doi:https://doi.org/10.1196/annals.1369.052
• Orellana-Serradell, O., Poblete, C. E., Sanchez, C., Castellón, E. A., Gallegos, I., Huidobro, C., . . . Contreras, H. R. (2015). Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep, 33(4), 1599-1608. doi:10.3892/or.2015.3746
• Pacher, P., & Mechoulam, R. (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Progress in Lipid Research, 50(2), 193-211. doi:https://doi.org/10.1016/j.plipres.2011.01.001
• Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006). The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocrine Reviews, 27(1), 73-100. doi:10.1210/er.2005-0009
• Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology, 153(2), 199-215. doi:10.1038/sj.bjp.0707442
• Pisanti, S., & Bifulco, M. (2017). Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. Trends in Pharmacological Sciences, 38(3), 195-198. doi:https://doi.org/10.1016/j.tips.2016.12.002
• Polito, S., MacDonald, T., Romanick, M., Jupp, J., Wiernikowski, J., Vennettilli, A., . . . Dupuis, L. L. (2018). Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. Pediatr Blood Cancer, 65(12), e27374. doi:10.1002/pbc.27374
• Pomeroy, M., Fennelly, J. J., & Towers, M. (1986). Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol, 17(3), 285-288. doi:10.1007/bf00256701
• Porter, B. E., & Jacobson, C. (2013). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior, 29(3), 574-577. doi:https://doi.org/10.1016/j.yebeh.2013.08.037
• Qamri, Z., Preet, A., Nasser, M. W., Bass, C. E., Leone, G., Barsky, S. H., & Ganju, R. K. (2009). Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther, 8(11), 3117-3129. doi:10.1158/1535-7163.Mct-09-0448
• Ramer, R., Schwarz, R., & Hinz, B. (2019). Modulation of the Endocannabinoid System as a Potential Anticancer Strategy. Frontiers in pharmacology, 10, 430-430. doi:10.3389/fphar.2019.00430
• Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & de Ceballos, M. L. (2005). Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. The Journal of Neuroscience, 25(8), 1904. doi:10.1523/JNEUROSCI.4540-04.2005
• Richfield, E. K., & Herkenham, M. (1994). Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Annals of Neurology, 36(4), 577-584. doi:https://doi.org/10.1002/ana.410360406
• Rog, D. J., Nurmikko, T. J., & Young, C. A. (2007). Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther, 29(9), 2068-2079. doi:10.1016/j.clinthera.2007.09.013
• Rog, D. J., Nurmikko, T. J., & Young, C. A. (2007). Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clinical Therapeutics, 29(9), 2068-2079. doi:https://doi.org/10.1016/j.clinthera.2007.09.013
• Sallan, S. E., Zinberg, N. E., & Frei, E., 3rd. (1975). Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med, 293(16), 795-797. doi:10.1056/nejm197510162931603
• Sánchez, C., de Ceballos, M. L., Gomez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G., . . . Guzmán, M. (2001). Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res, 61(15), 5784-5789.
• Sarfaraz, S., Afaq, F., Adhami, V. M., & Mukhtar, H. (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res, 65(5), 1635-1641. doi:10.1158/0008-5472.Can-04-3410
• Schley, M., Ständer, S., Kerner, J., Vajkoczy, P., Schüpfer, G., Dusch, M., . . . Konrad, C. (2009). Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull, 79(5), 333-337. doi:10.1016/j.brainresbull.2009.01.011
• Solas, M., Francis, P. T., Franco, R., & Ramirez, M. J. (2013). CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging, 34(3), 805-808. doi:https://doi.org/10.1016/j.neurobiolaging.2012.06.005
• Sredni, S. T., Huang, C.-C., Suzuki, M., Pundy, T., Chou, P., & Tomita, T. (2016). Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system. Child's Nervous System, 32(11), 2061-2067. doi:10.1007/s00381-016-3243-7
• Suraev, A., Lintzeris, N., Stuart, J., Kevin, R. C., Blackburn, R., Richards, E., . . . McGregor, I. S. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 10154. doi:10.1038/s41598-018-28127-0
• Svíženská, I., Dubový, P., & Šulcová, A. (2008). Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. Pharmacology Biochemistry and Behavior, 90(4), 501-511. doi:https://doi.org/10.1016/j.pbb.2008.05.010
• Szulakowska, A., & Milnerowicz, H. (2007). Cannabis sativa in the Light of Scientific Research. Advances in Clinical and Experimental Medicine, 16, 807-815.
• Tolón, R. M., Núñez, E., Pazos, M. R., Benito, C., Castillo, A. I., Martínez-Orgado, J. A., & Romero, J. (2009). The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Research, 1283, 148-154. doi:https://doi.org/10.1016/j.brainres.2009.05.098
• Touw, M. (1981). The Religious and Medicinal Uses of Cannabis in China, India and Tibet. Journal of Psychoactive Drugs, 13(1), 23-34. doi:10.1080/02791072.1981.10471447
• Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W., & Myers, L. W. (1987). Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse, 7(1), 39-50. doi:10.1300/j251v07n01_04
• Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., . . . Sharkey, K. A. (2005). Identification and Functional Characterization of Brainstem Cannabinoid CB₂ Receptors. Science, 310(5746), 329-332. doi:10.1126/science.1115740
• Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G., & Díaz-Laviada, I. (2011). Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ, 18(7), 1099-1111. doi:10.1038/cdd.2011.32
• Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis Journal, 10(4), 434-441. doi:10.1191/1352458504ms1082oa
• Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003). The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy. Journal of Pharmacology and Experimental Therapeutics, 307(1), 129. doi:10.1124/jpet.103.051920
• Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008). A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The journal of pain : official journal of the American Pain Society, 9(6), 506-521. doi:10.1016/j.jpain.2007.12.010
• Wu, J., Bie, B., Yang, H., Xu, J. J., Brown, D. L., & Naguib, M. (2013). Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiology of Aging, 34(3), 791-804. doi:https://doi.org/10.1016/j.neurobiolaging.2012.06.011
• Wu, X., Han, L., Zhang, X., Li, L., Jiang, C., Qiu, Y., . . . Fu, J. (2012). Alteration of endocannabinoid system in human gliomas. Journal of Neurochemistry, 120(5), 842-849. doi:https://doi.org/10.1111/j.1471-4159.2011.07625.x
• Xu, D., Wang, J., Zhou, Z., He, Z., & Zhao, Q. (2015). Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells Corrigendum in /mmr/13/1/1054. Mol Med Rep, 12(6), 7963-7970. doi:10.3892/mmr.2015.4477
• Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., & Mattison, P. G. (2012). MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. Journal of Neurology, Neurosurgery & Psychiatry, 83(11), 1125. doi:10.1136/jnnp-2012-302468
• Zuardi, A. W. (2006). History of cannabis as a medicine: a review. Brazilian Journal of Psychiatry, 28, 153-157. Retrieved from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462006000200015&nrm=iso
• Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry, 56(10), 485-486.